GPCM
TXG icon

Granite Point Capital Management’s 10x Genomics TXG Stock Holding History

Granite Point Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,000
Closed -$279K – 45
2023
Q1 		$279K Buy
+5,000
New +$233K 0.39% 38
2022
Q2 		– Sell
-6,000
Closed -$456K – 141
2022
Q1 		$456K Buy
+6,000
New +$525K 0.1% 104

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

Granite Point Capital Management's TXG Position: Q2 2023 in Review

Granite Point Capital Management sold out of 10x Genomics (TXG) in Q2 2023, closing a stake of 5,000 shares — an estimated $279K sold.

Granite Point Capital Management first reported a position in TXG in Q1 2022 and held it in 2 quarters. The position peaked at $456K in Q1 2022. 274 funds tracked by Wall St. Rank hold TXG as of Q2 2023.

  • Granite Point Capital Management reported no remaining 10x Genomics position as of Q2 2023 after selling out during the quarter.
  • Granite Point Capital Management sold 5,000 10x Genomics shares in Q2 2023, an estimated $279K.
  • Granite Point Capital Management first reported a position in 10x Genomics in Q1 2022 and held it in 2 quarters.
  • Granite Point Capital Management's 10x Genomics position peaked at $456K in Q1 2022.
  • 274 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2023.

Based on Granite Point Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.